Arcturus Therapeutics Holdings Inc

+0.13 (+0.73%)
Earnings Announcements

Arcturus Reports Strong Three-Month Durability Results From ARCT-154 Booster Trial

Published: 05/05/2022 12:53 GMT
Arcturus Therapeutics Holdings Inc (ARCT) - Arcturus Reports Strong Three-month Durability Results From Arct-154 Booster Trial.
Arcturus Therapeutics Holdings - Three-month Data From Arct-154 Booster Trial Show Persistent Neutralizing Antibody Activity Against Multiple Variants of Sars-cov-2.
Revenue is expected to be $3.54 Million
Adjusted EPS is expected to be -$1.84

Next Quarter Revenue Guidance is expected to be $9.62 Million
Next Quarter EPS Guidance is expected to be -$1.75

More details on our Analysts Page.